Provided by Tiger Trade Technology Pte. Ltd.

Inhibrx Biosciences

96.99
-0.9400-0.96%
Post-market: 96.990.00000.00%19:30 EDT
Volume:201.45K
Turnover:19.64M
Market Cap:1.42B
PE:-10.93
High:100.13
Open:99.30
Low:96.07
Close:97.93
52wk High:155.29
52wk Low:28.16
Shares:14.67M
Float Shares:8.64M
Volume Ratio:0.84
T/O Rate:2.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.8768
EPS(LYR):-9.0434
ROE:-1773.60%
ROA:-43.61%
PB:-26.86
PE(LYR):-10.72

Loading ...

Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges

Benzinga_recent_news
·
Apr 23

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, AT&T, Yesway

Reuters
·
Apr 23

Inhibrx price target raised to $300 from $150 at Stifel

TIPRANKS
·
Apr 23

Top Midday Stories: GE Vernova Shares Gain on Strong Q1 Earnings, Guidance; Vertiv Lifts Guidance After Q1 EPS, Revenue Beats, Shares Fall

MT Newswires Live
·
Apr 22

Inhibrx trading resumes

TIPRANKS
·
Apr 22

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM

Reuters
·
Apr 22

Sector Update: Health Care Stocks Edge Higher Premarket Wednesday

MT Newswires Live
·
Apr 22

Inhibrx’s cancer drug drawing interest from Merck, Ono, Reuters says

TIPRANKS
·
Apr 22

Inhibrx up 39% at $117 after report of interest from Merck in cancer assets

TIPRANKS
·
Apr 22

Merck, Rivals Show Interest in Inhibrx's Experimental Cancer Drug, Reuters Reports

MT Newswires Live
·
Apr 22

Inhibrx Biosciences Shares Jump 6.2% Premarket After Reuters Report Co's Experimental Cancer Drug Draws Interest From Merck, Rivals

THOMSON REUTERS
·
Apr 22

Exclusive-Merck, Rivals Interested in Inhibrx Experimental Cancer Drug Tied to Keytruda, Sources Say

THOMSON REUTERS
·
Apr 22

EXCLUSIVE-Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say

Reuters
·
Apr 22

Exclusive-Inhibrx Considers Spinoff of Two Cancer Therapies, Sources Say

THOMSON REUTERS
·
Apr 22

Inhibrx Biosciences Gives Updated Data From Cancer Treatment Study

Dow Jones
·
Apr 22

Inhibrx Provides Clinical Update on Ozekibart (Inbrx-109) in Late Line Colorectal Cancer

THOMSON REUTERS
·
Apr 22

Inhibrx to host webcast clinical update on ozekibart in late-line colorectal cancer

Reuters
·
Apr 21

Inhibrx to Host Webcast Presentation to Provide Clinical Update on Ozekibart (Inbrx-109) in Late Line Colorectal Cancer

THOMSON REUTERS
·
Apr 21

Stifel Initiates Inhibrx Biosciences at Buy With $150 Price Target

MT Newswires Live
·
Apr 08

Inhibrx Biosciences Initiated at Buy by Stifel

Dow Jones
·
Apr 08